Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 299 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 4 versions Re-verified since Jan 22, 2019, no change to tracked fieldsv296-v299
  2. Site details revised at 1 of 51 sitesv295
  3. Phase: Not applicable to Not specifiedv294 Show 9 more changesShow less
    • Trial status: Withdrawn to Active, Not Recruiting
    • Primary endpoints: 2 to 3
    • Enrollment target: 0 to 840
    • Primary completion date: Jan 2100
    • Interventions: flow cytometry (Other), reverse transcriptase-polymerase chain reaction (Genetic) to laboratory biomarker analysis (Other)
    • Eligibility criteria shortened, about 32 words
    • Secondary endpoints: 4 to 2
    • Study description shortened, about 67 words
    • Study arms: 0 to 1
  4. Re-verified, no change to tracked fieldsv293
  5. Trial status: Recruiting to Withdrawn
    • Lead sponsor: Cancer and Leukemia Group B to Alliance for Clinical Trials in Oncology
    • Enrollment target: estimated 450 to confirmed 0
    • Site details revised at 51 of 51 sites
    v292
Show 42 earlier versionsHide 42 earlier versions
  1. Study sites: 54 to 51v291
  2. Study sites: 53 to 54v290
  3. Study sites: 54 to 53v289
  4. Study sites: 53 to 54v288
  5. Study sites: 54 to 53v287
  6. Study sites: 53 to 54v286
  7. Study sites: 54 to 53v285
  8. Study sites: 53 to 54v284
  9. Study sites: 54 to 53v283
  10. Study sites: 52 to 54v282
  11. Study sites: 54 to 52v281
  12. Re-verified, no change to tracked fieldsv280
  13. Site contacts updated at 1 of 54 sitesv279
  14. Re-verified, no change to tracked fieldsv278
  15. Study sites: 55 to 54v277
  16. Study sites: 54 to 55v276
  17. Site contacts updated at 1 of 54 sitesv275
  18. Study sites: 55 to 54v274
  19. Study sites: 56 to 55v273
  20. Study sites: 55 to 56v272
  21. Study sites: 54 to 55v271
  22. Study sites: 55 to 54v270
  23. Study sites: 53 to 55v269
  24. Study sites: 54 to 53v268
  25. Study sites: 53 to 54v267
  26. Study sites: 54 to 53v266
  27. Study sites: 52 to 54v265
  28. Study sites: 54 to 52v264
  29. Study sites: 49 to 54v263
  30. Study sites: 50 to 49v262
  31. Study sites: 54 to 50v261
  32. Study sites: 53 to 54v260
  33. Study sites: 54 to 53v259
  34. Study sites: 52 to 54v258
  35. Study sites: 51 to 52v257
  36. Study sites: 50 to 51v256
  37. Study sites: 51 to 50v255
  38. Study sites: 50 to 51v254
  39. Study sites: 49 to 50v253
  40. Study sites: 48 to 49v252
  41. Site contacts updated at 1 of 48 sitesv251
  42. Study sites revised (48)v250
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research trial studies molecular genetic features in blood and tissue samples from patients with newly diagnosed acute lymphoblastic leukemia or acute promyelocytic leukemia. Studying samples of blood and tissue from patients with acute lymphoblastic leukemia or acute promyelocytic leukemia in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Trial Details
NCT Number NCT00003861
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Leukemia, Acute Lymphoblastic Leukemia, Acute Promyelocytic Leukemia
Related terms Leukemia, Leukemia, Promyelocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 840 participants
Start Date
Primary Completion (estimated)
Updated on ClinicalTrials.gov